Singapore markets open in 8 hours 42 minutes

Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
139.64-2.99 (-2.10%)
At close: 04:00PM EDT
139.56 -0.08 (-0.06%)
After hours: 05:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close142.63
Open144.20
Bid138.97 x 800
Ask140.66 x 1400
Day's range136.11 - 144.46
52-week range105.43 - 192.79
Volume1,692,560
Avg. volume1,072,248
Market cap25.704B
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

    BOTHELL, Wash., May 16, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen’s Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found.

  • Business Wire

    Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

    BOTHELL, Wash., May 09, 2022--The Board of Directors of Seagen Inc. (Nasdaq: SGEN) today announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence. The company is aware of an alleged incident of domestic violence that occurred recently at Dr. Siegall’s home. Dr. Siegall has denied these allegations and has informed the company that he is engaged in a divorce. The Board of Directors has formed a committee of independent directors and is conducting a thorough investig

  • Business Wire

    Seagen Reports First Quarter 2022 Financial Results

    BOTHELL, Wash., April 28, 2022--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline.